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It was shown recently that dimethylfumarate (DMF), an active ingredient of the oral antipsoriaticum Fumaderm, has an antiproliferative effect on keratinocytes (Thio et al, 1994) , lymphocytes (Nieboer et al, 1990) , and ®broblasts ( Van der Schroeff et al, 1989) . DMF also inhibits T cell cytokine secretion (Ockenfels et al, 1998) , expression on keratinocytes of intercellular adhesion molecule 1 (ICAM-1) (Sebo Èk et al, 1994a) , and cytokine-induced CAM expression on endothelial cells (Vandermeeren et al, 1997) . Normal human dermal ®broblasts (NHDF) are also involved in the initiation of an in¯ammatory response in the skin. Proin¯ammatory cytokines produced by keratinocytes can upregulate ICAM-1 on dermal ®broblasts (Boxman et al, 1996) , whose expression can also be inhibited by DMF, as shown in this study.
The mode of action of DMF is not completely understood, but the inhibitory spectrum of DMF on cytokine-inducible genes includes interleukin-6 (IL-6), E-selectin, vascular adhesion molecule 1, and ICAM-1 (Vandermeeren et al, 1997; Ockenfels et al, 1998) , all sharing a nuclear factor-kB (NF-kB) responsive element in the cytokine-inducible enhancer of their gene promoters (May and Gosh, 1998) . This might indicate that DMF's molecular mechanism of action interferes with the signaling cascades that activate NF-kB (Prochaska et al, 1994) .
NF-kB, a ubiquitous transcription factor, is a pivotal regulator of immune responses, in¯ammation, cell proliferation, and apoptosis (Baeuerle and Henkel, 1994; Gilmore et al, 1996) . NF-kB complexes are stored in the cytoplasm of unstimulated cells as inactive complexes through interactions with a group of inhibitory proteins called inhibitors of kB (IkB), such as IkBa, IkBb, IkBe. Alternatively, IkB-like domains occur in NF-kB precursor proteins p105 of NFkB1 (p50) and p100 of NFkB2 (p52) (Brown et al, 1995; Traenckner et al, 1995) . Cytokines, such as IL-1a and tumor necrosis factor a (TNF-a), rapidly induce NF-kB DNA binding (Barnes and Karin, 1997) , which comprises homodimers and heterodimers of Rel proteins such as RelA (p65), RelB, c-Rel, NF-kB1 (p105/p50), and NF-kB2 (p100/p52) (Siebenlist et al, 1994) . This study shows that, in addition to inhibition of cytokineinduced ICAM-1 expression, DMF also delays the reappearance of the different IkB subunits in the cytoplasm of NHDF cells, possibly by modifying the nuclear targeting machinery of NF-kB. The molecular analysis of DMF's inhibitory effects have led to the observation that inhibition of the translocation of NFkB1 (p50), but not of RelA (p65), may underlie DMF's anti-in¯ammatory effects.
MATERIALS AND METHODS
Cell culture NHDF, derived from neonatal skin, were obtained from Clonetics (San Diego, CA) and cultured in either ®broblast growth medium (Clonetics) or Optimem with Glutamax-1 (Gibco BRL, Life Technologies, Paisley, U.K.) supplemented with 5% fetal bovine serum (HyClone Laboratories, Logan, UT), 2 mM L-glutamine (Gibco BRL), 4 mg per ml gentamycin (Gibco BRL), and 1 mM sodium pyruvate (Gibco BRL). They were used within the ®rst seven passages.
Reagents DMF and n-tosyl-phenylalanine-chloromethylketon (TPCK) were purchased from Sigma (St. Louis, MO). Recombinant human TNF-a and recombinant human IL-1a were obtained from Genzyme (Cambridge, MA). Anti-ICAM-1 monoclonal antibody was purchased from Bender Medsystems (Vienna, Austria). Normal goat serum was obtained from DakoPatts (Glostrup, Denmark), and a secondary horseradish-peroxidaselabeled goat antimouse antibody from Amersham (Buckinghamshire, U.K.). Antibodies anti-p50 and anti-p65 to NF-kB subunits were purchased from Biomol Research Labs (Plymouth Meeting, PA). Polyclonal antibodies against IkB were obtained from Santa Cruz Biotechnology (Santa Cruz, CA): anti-IkBa, anti-IkBb, and anti-IkBe. Anti-c-Rel antibody was also purchased from Santa Cruz Biotechnology.
Enzyme-linked immunosorbent assay (ELISA) NHDF were seeded at 5000 cells per well in 96-well tissue culture plates (Nunc, Roskilde, Denmark). Con¯uent cells received fresh medium plus pharmacologic compounds at the indicated concentrations 1 h prior to stimulation. TNFa was added at 10 ng per ml and IL-1a at 3 U per ml. ICAM-1 expression levels were determined after 24 h. Cell monolayers were washed ®ve times with phosphate-buffered saline (PBS), ®xed for 15 min in 2% paraformaldehyde, and blocked with 2% normal goat serum. After blocking, a primary mouse antihuman anti-ICAM-1 monoclonal antibody (50 ng per ml) was incubated for 3 h at room temperature or overnight at 4°C. The monolayers were washed ®ve times, blocked, and incubated for 1 h with a horseradish-peroxidase-conjugated goat antimouse antibody (Amersham) diluted in 1% bovine serum albumin/PBS. The amount of cell adhesion molecules was detected by a colorimetric method, using phosphate-citrate buffer with urea hydrogen peroxide tablets (Sigma) and ortho-phenylenediamine dihydrochloride (Sigma) as substrates. Adding 2 N sulfuric acid stopped the reaction and the absorbance was measured on an ELISA plate reader at 490-650 nm. In a typical cell ELISA experiment, quadruplicate plates are accompanied by a mitochondrial tetrazolium (MTT) plate (method see below) to assess the effects of the treatment on cell viability. Cell ELISA values are expressed as OD 490±650nm /OD 540± 650nm of the accompanying well in the MTT test.
Cell viability Cell viability was assessed with an MTT assay. Brie¯y, NHDF cells were treated under the same conditions as described for the cell ELISA experiments. After the incubation, 25 ml per well of an MTT solution [5 mg per ml MTT (Sigma) in Ca 2+ /Mg 2+ -free PBS] was added and incubated for 2 h. The medium was aspirated and replaced with 100 ml per well isopropanol. The plates were shaken for 15 min and the OD was measured at 540-650 nm.
Protein isolation NHDF cells were grown to 80%±90% con¯uence in individual 75 cm 2¯a sks for preparation of extracts for each experimental point. Following 1 h pretreatment with 100 mM DMF or 0.1% dimethylsulfoxide and appropriate stimulus, ®broblasts were washed three times in cold PBS, and protein was then extracted from the cells; cells were resuspended in buffer A [10 mM HEPES KOH (pH 7.9) at 4°C, 1.5 mM MgCl 2 , 10 mM KCl, 300 mM sucrose, 0.5% Nonidet P-40 with protease inhibitor mixture (0.5 M dithiothreitol and 1 mM Pefabloc)]. Cells were incubated for 5 min on ice and centrifuged for 10 s at 14,000 rpm at 4°C. The resulting supernatant was the cytoplasmic fraction and cells were washed once in buffer A. Pellets were resuspended in buffer C [20 mM HEPES KOH (pH 7.9), 20% glycerol, 100 mM NaCl, 0.2 mM ethylenediamine tetraacetic acid, 100 mM KCl with protease inhibitor mixture] and frozen and thawed in liquid nitrogen. Next, pellets were brie¯y sonicated and centrifuged at 14,000 rpm, resulting in the nuclear fraction extracts. The supernatant was collected and the protein concentration was quanti®ed using the Bio-Rad (Richmond, CA) protein assay. The protein extracts were then stored at ±70°C until used for electrophoretic mobility shift assay (EMSA) and western blot analysis.
Protein immunoblotting A total of 25±30 mg of protein extracts was denatured at 95°C in 2 Q Laemmli buffer for 5 min, loaded onto 12% Tris glycine sodium dodecyl sulfate (SDS) gel (BioRad), and electrophoresed at 30 mA constant. Protein was semidry blotted onto 0.2 mm polyvinylidene di¯uoride membrane (Roche Diagnostic Corporation, Indianapolis, IN) in transfer buffer for 1 h at 1 mA per cm 2 . The membranes were blocked with 5% (wt/vol) nonfat dry milk (BioRad) in PBS for 1 h, and incubated with primary antibody overnight at 4°C. The membranes were then washed in PBS-0.1% Tween-20 for 5 min with ®ve changes of buffer, and incubated for 1 h with a horseradish-peroxidase-conjugated goat antirabbit antibody (New England Biolabs, Beverly, MA) in 1:2000 dilution for 1 h at room temperature. After washing, the bands of interest were visualized by chemiluminescence (Pierce, Rockford, IL) and the light signal was captured by a Lumi-Imager apparatus (Roche Diagnostic Corporation). Polyclonal antibodies to IkBb, IkBe, p65, and p50 showed some nonspeci®c bands. Bands of interest are indicated by arrows and veri®ed by means of their exact molecular weight.
EMSA kB consensus oligo, 5¢-AGCTAGAGGGGACTTTCCGAG-AGG, and the complementary strand were custom synthesized by Eurogentec (Eurogentec, Liege, Belgium). The kB oligonucleotides were annealed by mixing the single stranded oligonucleotides in a molar ratio of 1:1, incubating them for 10 min at 95°C, and cooling down slowly to 4°C. NF-kB DNA binding was analyzed by incubating 8 mg nuclear proteins for 30 min at room temperature with the NF-kB speci®c 32 P-labeled oligonucleotide probe. Binding buffer consisted of 20 mM HEPES, pH 7.5, 60 mM KCl, 4% Ficoll 400, 2 mM dithiothreitol, 100 mg per ml poly-[d(I-C)], and 1 mg per ml bovine serum albumin. Samples were analyzed by electrophoresis on a 5% native polyacrylamide gel that was run for 1.5 h at 100 V in a 0.5 Q TBE buffer, pH 8.0. DNA-nucleoprotein complex speci®city was determined by coincubation of nuclear extracts with unlabeled homologous competitor DNA. For competition experiments, 100-fold molar excess of unlabeled oligonucleotide was included in the binding reaction. The following antibodies were used in supershift experiments: antibodies anti-p50 (sc-114X) and anti-p65 (sc-109X) to NF-kB subunits were purchased from Santa Cruz Biotechnology. Brie¯y, antibodies were added to the nuclear extracts (1 mg polyclonal antiserum per 8 mg nuclear protein) and incubated for 1 h before the binding reaction.
Transfections NHDF cells were seeded at a density of 1 Q 10 6 cells per 75 cm 2¯a sk. Twenty-four hours later, cells were transfected by Lipofectamine (Gibco BRL) with constant 10 mg per 75 cm 2¯a sk of the plasmid p(kB) 3 LUC, which has been described previously (Plaisance et al, 1997) and contains in front of the luciferase gene a minimal promoter for the concanavaline A gene (a TATA binding site) preceded by three copies of the NF-kB binding site of the major histocompatibility complex II gene. Four hours after transfection, cells were trypsinized and seeded at 2 Q 10 5 cells per 12 wells. At 42 h post transfection, cells were exposed to 100 mM DMF or 0.1% dimethylsulfoxide (DMSO) vehicle for 1 h and further stimulated with 10 ng per ml TNF-a for 4 h. This transfection was performed``in bulk''; therefore it was not necessary to correct results for transfection ef®ciency. Transcriptional activity was corrected for total protein content and the protein concentration was quanti®ed using BioRad protein assay.
RESULTS
DMF inhibits cytokine-induced ICAM-1 expression in NHDF The effect of DMF on 10 ng per ml TNF-a-or 3 U per ml IL-1a-induced ICAM-1 expression was studied using an in situ ELISA (Fig 1) . Treatment of the NHDF monolayers diminished the expression of ICAM-1, both IL-1a and TNFa induced, with an IC50 value of 30 mM, comparable with the IC50 of DMF on endothelial cells (Fig 1) . Inhibition was complete at a dose of 300 mM DMF. A cell viability assay was performed in parallel with each in situ ELISA. DMF treatment was shown not to affect cell viability of NHDF in parallel MTT assays (Fig 1) following 24 h of incubation, in contrast to 30 mM TPCK, a proteasome inhibitor, which proved to be toxic to NHDF cells in similar conditions. DMF delays re-synthesis of IkBs To further understand DMF's inhibitory effect on cytokine-induced ICAM-1 expression, cytoplasmic extracts were subjected to western blotting to assay the degradation kinetics of the different IkBs in NHDF cells. It was shown (Fig 2) that after 100 mM DMF or 0.1% DMSO pretreatment for 1 h and subsequent 10 ng per ml TNF-a or 25 U per ml IL-1a stimulation, IkBa and IkBe disappeared from the cytoplasm after 15 min. IkBa proteins were re-synthesized after 30 min and IkBb and IkBe reappeared only after approximately 4 h. There appeared to be minor differences in the degradation kinetics for IkBs. IkBa and IkBe are being degraded slightly faster (at 15 min), whereas IkBb levels are minimal at 30 min following cytokine stimulation. Re-synthesis of the IkBs in NHDF was shown to be fast for IkBa and somewhat slower for IkBb and IkBe, as demonstrated in other cells such as human U937 monocytic cells (Nasuhara et al, 1999) . Pre-incubation of con¯uent NHDF cells for 1 h with DMF followed by cytokine stimulation and incubation for different time periods showed that DMF had minor inhibitory effects on the degradation of IkBa and IkBe; however, IkBb degradation was clearly inhibited. The reappearance of all IkBs in the cytoplasm was signi®cantly delayed by DMF pretreatment (Fig 2) . DMF inhibits NF-kB1 (p50) but not RelA (p65) nuclear accumulation In parallel, the nuclear extracts of cytokinetreated NHDF cells were western blot analyzed for the nuclear targeting kinetics of NF-kBs. Both cytokines, 10 ng per ml TNF-a and 25 U per ml IL-1a, induced an accumulation of the NF-kB subunits p50 and p65 in nuclear extracts after 15 min (Fig 3) . c-Rel was found to be nuclear in unstimulated ®broblasts, and shifts to the nucleus were shown not to occur following treatment with either TNF-a or IL-1a (Fig 3) . A 1 h DMF pretreatment did not in¯uence p65 (nor c-Rel) nuclear translocation in western blots; however, the appearance of p50 in the nucleus was clearly affected by DMF (Fig 3) . After TNF-a stimulation, p50 translocation was still inhibited up to 4 h, but after IL-1a stimulation, delayed p50 nuclear accumulation appeared in the nucleus after 4 h (Fig 3) .
Functional inhibition by DMF of NF-kB signaling To further demonstrate that the inhibitory effects of DMF on ICAM-1 expression (and on delayed kB re-synthesis) were mediated by an NF-kB-dependent mechanism, we tested whether DMF was capable of inhibiting NF-kB protein binding to its kB DNA binding site, by radioactive gel-shift performed with kB consensus oligonucleotides. NHDF cells, 80%±90% con¯uent, were untreated or stimulated with 10 ng per ml TNF-a for 2 h. A TNF-ainducible protein-DNA complex is clearly shown in Fig 4(a) . A 100-fold molar excess of unlabeled homologous competitor NF-kB oligonucleotide strongly reduced the TNF-a-induced complex. This retarded complex was further identi®ed by supershift assays. In a consecutive experiment (Fig 4b) , again a TNF-a-inducible protein-DNA complex was clearly shown versus a medium control. When cells were pretreated with 100 mM DMF, DNA oligo binding versus vehicle (DMSO) control in TNF-a-stimulated cells was clearly decreased. When nuclear extracts of TNF-atreated cells were preincubated with an anti-p50 antibody or an anti-p65 antibody, the cytokine-inducible complex band was less intense and a supershift was observed with anti-p50 and anti-p65 antibodies, indicating that both p50 and p65 are components of the NF-kB binding complexes.
Finally, we tested if DMF had an effect on the NF-kB transcriptional activity by transient transfection experiments of NHDF cells using a pNFkB::luciferase reporter gene construct containing three repeat NF-kB binding sites. A 100 mM DMF pretreatment of 1 h was shown to inhibit the transcription initiation capacity of NF-kB in NHDF cells stimulated for 4 h with 10 ng per ml TNF-a (Fig 5) or with 25 U per ml IL-1a (data not shown). Total protein concentration of the individual samples was identical after compound treatment.
DISCUSSION
Several clinical studies have shown that oral administration of derivatives of fumarate is an effective treatment for psoriasis patients (Mrowietz et al, 1998) .``Fumaric acid therapy'' consists of the oral administration of a mixture of esteri®ed fumaric acid derivatives, in which DMF is thought to be the main active ingredient as it exerts the most pronounced antiproliferative activity in vitro in thè`s ubtoxic dose range'' (Thio et al, 1994) on keratinocytes (Sebo Èk et al, 1994b) , lymphocytes (Nieboer et al, 1990) , and ®broblasts ( Van der Schroeff et al, 1989) . Due to its methylesters, DMF is a lipid-soluble compound, with good cell permeability. Following esterase conversion to fumarate, DMF enters the citric acid cycle at the level of succinate dehydrogenase. This in turn is thought to cause inhibition of cell functions, such as a decrease in proliferation and perhaps cytotoxicity (Van der Schroeff et al, 1989) . In our observations, as in those for endothelial cells (Vandermeeren et al, 1997) , 100 mM DMF showed no cytotoxic effects on NHDF monolayer cultures even after prolonged incubation times of 24 h either in the presence or absence of cytokines. This critically suggests that the observed inhibitory effects do not result from a direct cytotoxic mechanism.
Although the aforementioned studies underscore DMF's antiproliferative effects on cells, there is a growing body of evidence for an anti-in¯ammatory mechanism of DMF. Such a mechanism is re¯ected by observations of immune cells: suppression of production and release of in¯ammatory mediators in granulocytes (Barker et al, 1991b) , augmentation of T helper cell 2 cytokine responses (de Jong et al, 1996) , modulation of T cell cytokine secretion, and inhibition of cytokines of the psoriatic cytokine network (Ockenfels et al, 1998) . On the other hand, DMF also inhibits cytokine-induced activation of peripheral cells such as adhesion molecule expression in HUVEC cells (Vandermeeren et al, 1997) and in this report cytokine-induced ICAM-1 expression in NHDF cells. A widely accepted model for the anti-in¯ammatory mode of action of DMF is the intracellular induction of enzymes responsible for the synthesis and the maintenance of the antioxidant glutathione, as shown for the monocytoid U1 cell line and human retinal pigment epithelial cells (Prochaska et al, 1994; Nelson et al, 1999) . Cytokine stimulation of cells is known to increase reactive oxygen levels in the cells and leads to modi®cation of the IkB-NFkB balance. DMF's antioxidant property might partially explain our observations on the inhibition of the cytokine-induced ICAM-1 upregulation in NHDF. Previous studies have shown that DMF can abrogate the NF-kB pathway. This was demonstrated by the EMSA technique (NF-kB consensus oligonucleotide) in a phorbolmyristate-acetate-stimulated monocytoid U1 cell line (Prochaska et al, 1994) , and in arsenite-activated porcine aortic endothelial cells (Barchowsky et al, 1996) . Besides phorbol-myristate-acetate-and arsenite-induced NF-kB binding, this study now demonstrates that DMF also inhibits NF-kB binding in reporter assays and gel mobility assays following TNF-a and IL-1a stimulation (IL-1a data not shown).
Based on these observations, DMF is one on an increasing list of compounds that display inhibition of NF-kB activation. Experiments to identify where exactly in the NF-kB pathway DMF acts have led to the observation that DMF speci®cally inhibited p50 nuclear translocation without affecting p65 nuclear translocation. This observation of a p65-independent p50 inhibition supports the data of a recent study (Heissmeyer et al, 1999) that suggested a bifurcation of the NF-kB-activating pathways downstream of the IkB kinase (IKK) complex to IkBa and p105 complexes. Our observations in NHDF pinpoint DMF's putative target of action upstream of p50 nuclear accumulation, perhaps at the level of p105 degradation, as has been shown for glucocorti- Figure 2 . DMF delays re-synthesis of IkBs. DMF (r) and DMSO solvent control (n). NHDF cells were treated with 0.1% DMSO or 100 mM DMF for 60 min and then stimulated with TNF-a (10 ng per ml) or IL-1a (25 U per ml) for 0, 15, 30, 60, and 240 min. Cytosolic protein was extracted and 30 mg of protein was subjected to SDS-PAGE followed by immunoblotting with IkBa, IkBb, and IkBe antibodies using the enhanced chemiluminescence technique as described in Materials and Methods. Shown is a representative result of three independent experiments. coids in vivo (Cornstein et al, 1999) . Our data do not exclude a mechanism of DMF on nuclear regulatory components of kB signaling such as Bcl-3, an IkB-like nuclear protein that activates cytoplasmic p50 homodimers or p50-p105 heterodimers and translocates them to the nucleus (Watanabe et al, 1997) . The close correlation between the kinetics of p50 nuclear accumulation and reappearance of the three IkBs following DMF treatment suggests that p50 is an essential regulator in IkB re-synthesis and that possibly p65 alone is not suf®cient to drive IkB transcription in NHDF cells.
The speci®city of DMF's inhibitory effect on NFkB1/p50 speci®c nuclear accumulation has not been observed ± to the best of our knowledge ± for other compounds that interfere with kB signaling. Aspirin inhibits TNF-a-induced NF-kB mobilization in human endothelial cells (Weber et al, 1995) , and salicylates and avonoids in general are thought to mediate this effect through inhibition of IKK in TNF-a-induced endothelial cells (Bayon et al, 1999; Tsai et al, 1999; Yamamoto et al, 1999) . Curcumin (diferuloylmethane) has been proposed to inhibit NF-kB signaling (Kumar et al, 1998) , possibly through direct protein binding and modi®cation of NFkB1/p50 in Jurkat T lymphoma cells, like herbimycin A ± a tyrosine kinase inhibitor ± binds directly with p50 in T lymphocytes (Mahon and O'Neill, 1995; Brennan and O'Neill, 1998) , or by inhibiting a signal leading to and upstream of NF-kB-inducing kinase (NIK) and IKK in human colonic epithelial cells (Jobin et al, 1999) . The antioxidant pyrrolidine dithiocarbamate (PDTC) inhibited NF-kB in TNF-a-induced human endothelial cells and human ®broblasts in an EMSA assay (Ferran et al, 1995; Kawai et al, 1995) . PDTC requires zinc for NFkB inhibition in bovine endothelial cells, however (Kim et al, 1999) . N-(3-aminopropionyl)-L-histidinato zinc (polaprezinc) downregulates NF-kB by an inhibition of IkBa phosphorylation in gastric epithelial cells (Shimada et al, 1999) . Proteasome inhibitors in an intestinal epithelial cell line (Jobin et al, 1998) , protein tyrosine kinase inhibitors in human myeloid T cells (Natarajan et al, 1998) , and protein tyrosine phosphatase inhibitors in human endothelial cells (Dhawan et al, 1997) have all been shown to interact with NF-kB signaling by a partially understood molecular mechanism. The mechanism of action of glucocorticoids has been extensively investigated, but their mode of action in NFkB signaling is still controversial: both inhibition and stimulation of NF-kB or IkBa have been observed (for a review see Dumont et al, 1998; McKay and Cidlowski, 1998). 1a,25-dihydroxyvitamin D 3 targets only DNA binding of NF-kB in human ®broblasts but does not inhibit nuclear accumulation of the subunits p50 and p65 (Harant et al, 1998) , perhaps through a squelching (Freedman, 1999) or phosphorylation-dependent mechanism. 3-deazaadenosine, an S-adenosylhomocystein hydrolase inhibitor, has a dual Figure 3 . DMF inhibits NFkB1 (p50) but not RelA (p65) nuclear accumulation. DMF (n) and DMSO solvent control (r). Vehicle (0.1% DMSO) or 100 mM DMF treatments were performed for 60 min and then stimulated with TNF-a (10 ng per ml) or IL-1a (25 U per ml) for 0, 15, 30, 60, and 240 min. Nuclear protein was extracted and 30 mg of protein was subjected to SDS-PAGE followed by immunoblotting of p65, p50, and c-Rel, using the enhanced chemiluminescence technique as described in Materials and Methods. Translocation of c-Rel and p65 was unchanged after DMF treatment. Cells pretreated with DMF, however, clearly inhibited or delayed p50 translocation to the nucleus. Shown is a representative result of three independent experiments.
effect on NF-kB regulation by blocking of p65 (RelA) phosphorylation without reduction of its nuclear translocation and by inhibition of DNA binding activity in mouse macrophages (Jeong et al, 1999) . On the other hand, mesalamine, an anti-in¯ammatory aminosalicylate, in epithelial cells (Egan et al, 1999) and genistein in human U937 monocytic cells (Nasuhara et al, 1999) inhibit cytokine-stimulated NF-kB-dependent transcription without preventing IkB degradation or nuclear translocation and DNA binding of the transcriptionally active NF-kB proteins p65, p50, and/or cRel, suggesting the existence of additional mechanisms that regulate NF-kB activation. Heyninck et al (1999) demonstrated the existence of at least two different NF-kB pathways: a NIKmediated pathway leading to translocation of NF-kB to the nucleus, and a NIK-independent pathway leading to transactivation of NF-kB. Another study (Vlahopoulos et al, 1999) demonstrated that, in U937 cells, TNF-a induces a delayed reactive-oxygenspecies-dependent signaling pathway that is required for NF-kB transcriptional activation and is separable from that required for its nuclear translocation. DMF could possibly attack, besides nuclear translocation of p50, such a``transactivation speci®c pathway of NF-kB''. In this way p65 could still be translocated to the nucleus and an NF-kB reporter construct could be abrogated, maybe by inhibiting the NF-kB p65 coactivator CBP/p300 (Zhong et al, 1998) .
In conclusion, the in vitro data for normal human dermal ®broblasts critically suggests that the p50 subunit of kB signaling may be a target relevant to the anti-in¯ammatory activity of DMF in psoriasis. Further studies will focus on the targets upstream and downstream of p50 that are most probably tackled by DMF. . DMF inhibits NF-kB-mediated gene expression. NHDF cells were transfected with a minimal promoter for the concanavaline A gene containing three repeats NF-kB binding sites, with a terminal luciferase, and exposed to 100 mM DMF or 0.1% DMSO vehicle for 1 h and further induced for 4 h with 10 ng per ml TNF-a. Cells were then lyzed and assayed for luciferase activity. Transcriptional activity was corrected for total protein content. The results of three separate experiments are included in the graphs. Values represent means T SD with n = 3.
